NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances ...
Two patients in the Phase 1/2a trial of troculeucel, an NK cell therapy for Alzheimer's disease, improved from moderate to mild AD after three months at the highest dose of 6 billion cells per treatment. The first Phase 2 patient was dosed at the same high dose, marking progress in the trial.
Reference News
NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances ...
Two patients in the Phase 1/2a trial of troculeucel, an NK cell therapy for Alzheimer's disease, improved from moderate to mild AD after three months at the highest dose of 6 billion cells per treatment. The first Phase 2 patient was dosed at the same high dose, marking progress in the trial.